USPTO Patent Grant: Antibody Inhibitors for Staphylococcus Aureus Treatment

The USPTO has granted patent US12583913B2 for antibody inhibitors targeting Staphylococcus aureus, specifically coagulases SC and vWbp. This patent covers therapeutic methods and detection techniques utilizing these monoclonal antibodies.

USPTO Patent Grant for T Cell Antigen Receptor Complex

The USPTO has granted patent US12583910B2 to Tsinghua University for a T cell antigen receptor complex and its preparation method. This patent covers antibodies, T cell receptors, and immune cells designed to recognize pMHC complexes and activate T cells for therapeutic use.

USPTO Patent Grant: Modified Plasma Clotting Factor VIII

The USPTO has granted patent US12583907B2 to AAVnerGene, INC. for modified human factor VIII polypeptides with enhanced activity. These polypeptides and their encoding viral vectors are intended for treating FVIII deficiencies, such as hemophilia A.

USPTO Patent Grant: DNA-binding domain transactivators

The USPTO has granted a patent (US12583902B2) to the University of Massachusetts for DNA-binding domain transactivators and their uses. The patent covers recombinant adeno-associated viruses (rAAVs) designed to modify target gene expression in cells.

USPTO Patent Grant for Caged-Degron Molecular Feedback Circuits

The USPTO has granted patent US12583896B2 to The Regents of the University of California for caged-degron-based molecular feedback circuits. The patent covers methods of modulating signaling pathways in cells using these circuits, with a filing date of January 6, 2020.

USPTO Patent Grant US12583892B2: Conus Peptides for Neurodegenerative Conditions

The USPTO has granted patent US12583892B2 to Technion Research and Development Foundation Limited for modified Conantokin peptides and their use in treating neurodegenerative conditions. The patent covers specific peptide forms, nucleic acids encoding them, and compositions for modulating NMDA receptors.

USPTO Patent Grant for Peptides Treating Type 1 Diabetes

The USPTO has granted patent US12583891B2 to PHOENIX ALPHA for peptides and methods used in the treatment of type 1 diabetes. The patent covers specific peptide sequences and their application in generating cytolytic CD4+ T cells.

Bi-specific Peptides for Cancer Treatment Granted Patent

The USPTO has granted a patent (US12583888B2) to the University of Tartu for bi-specific peptides designed to target cancer cells and the extracellular matrix. These peptides bind to fibronectin extra domain B (FN-EDB) and/or tenascin-C C domain (TNC-C). The patent was granted on March 24, 2026.

USPTO Patent Grant for Tumor Diagnosis and Treatment

The USPTO has granted patent US12583937B2 to Genentech, Inc. for compositions and methods related to the diagnosis and treatment of tumors in mammals. The patent, filed on March 16, 2022, includes 6 claims.

USPTO Grants Patent for Anti-CD73 Antibody and Use

The United States Patent and Trademark Office (USPTO) has granted patent US12583933B2 to BIOTHEUS INC. for an anti-CD73 antibody and its use in enhancing immune response and treating tumors. The patent was filed on August 28, 2020, and is effective March 24, 2026.